

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ML STRATEGIES, LLC**

2. Address:

701 PENNSYLVANIA AVENUE, NW SUITE #900, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: STEVEN E. IRIZARRY

Telephone: 202-434-7440

E-mail (optional): seirizarry@mlstrategies.com

Senate ID #: 25603-1115

House ID #: 33962055

7. Client Name:  Self

**NOVARTIS PHARMACEUTICALS, INC.**

## TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ML STRATEGIES, LLC Client Name: NOVARTIS PHARMACEUTICALS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Pharmaceutical and life sciences issues: Federal Food, Drug and Cosmetic Act (21 USC 9)

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUSE, MARK

Covered Official Position (if applicable):

Name: IRIZARRY, STEVEN

Covered Official Position (if applicable): SENIOR COUNSEL SENATE SPECIAL COMMITTEE ON AGING

Name: LEITER, DAVID

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ML STRATEGIES, LLC Client Name: NOVARTIS PHARMACEUTICALS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Pharmaceutical and life sciences issues: Federal Food, Drug and Cosmetic Act (21 USC 9)

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUSE, MARK

Covered Official Position (if applicable):

Name: IRIZARRY, STEVEN

Covered Official Position (if applicable): SENIOR COUNSEL SENATE SPECIAL COMMITTEE ON AGING

Name: LEITER, DAVID

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ML STRATEGIES, LLC Client Name: NOVARTIS PHARMACEUTICALS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Pharmaceutical coverage and reimbursement issues

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUSE, MARK

Covered Official Position (if applicable):

Name: IRIZARRY, STEVEN

Covered Official Position (if applicable): SENIOR COUNSEL SENATE SPECIAL COMMITTEE ON AGING

Name: LEITER, DAVID

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ML STRATEGIES, LLC Client Name: NOVARTIS PHARMACEUTICALS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: SCI (one per page)

16. Specific lobbying issues:

Pharmaceutical and life sciences issues: Federal Food, Drug and Cosmetic Act (21 USC 9)

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUSE, MARK

Covered Official Position (if applicable):

Name: IRIZARRY, STEVEN

Covered Official Position (if applicable): SENIOR COUNSEL SENATE SPECIAL COMMITTEE ON AGING

Name: LEITER, DAVID

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 17, 2006

Printed Name and Title: Steven E. Irizarry, Vice President of Government R -